{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:53:36Z","timestamp":1775109216552,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["advancesinpediatrics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pediatrics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.yapd.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T08:15:42Z","timestamp":1683879342000},"page":"145-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chronic Myeloid Leukemia in Children and Adolescents"],"prefix":"10.1016","volume":"70","author":[{"given":"Moran","family":"Gotesman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Raheel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard H.","family":"Panosyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.yapd.2023.04.002_bib1","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1002\/cncr.23866","article-title":"Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999","volume":"113","author":"Linabery","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.yapd.2023.04.002_bib2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.yapd.2023.04.002_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","article-title":"Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions","volume":"62","author":"Hijiya","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"10.1016\/j.yapd.2023.04.002_bib4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12185-015-1893-y","article-title":"Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia","volume":"103","author":"Mendizabal","year":"2016","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.yapd.2023.04.002_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11899-022-00673-5","article-title":"Management of chronic myeloid leukemia in children and young adults","volume":"17","author":"Ford","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"10.1016\/j.yapd.2023.04.002_bib6","doi-asserted-by":"crossref","first-page":"e27827","DOI":"10.1002\/pbc.27827","article-title":"Management of chronic myeloid leukemia in children and adolescents: recommendations from the Children's Oncology Group CML Working Group","volume":"66","author":"Athale","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.yapd.2023.04.002_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2141.2000.02137.x","article-title":"The story of chronic myeloid leukaemia","volume":"110","author":"Geary","year":"2000","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.yapd.2023.04.002_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJM198601233140403","article-title":"Bone marrow transplantation for patients with chronic myeloid leukemia","volume":"314","author":"Goldman","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.yapd.2023.04.002_bib9","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1097\/HS9.0000000000000468","article-title":"Chronic myeloid leukemia in 2020","volume":"4","author":"Hehlmann","year":"2020","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.yapd.2023.04.002_bib10","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.yapd.2023.04.002_bib11","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5750","key":"10.1016\/j.yapd.2023.04.002_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/283826a0","article-title":"Abelson murine leukaemia virus protein is phosphorylated in\u00a0vitro to form phosphotyrosine","volume":"283","author":"Witte","year":"1980","journal-title":"Nature"},{"issue":"6020","key":"10.1016\/j.yapd.2023.04.002_bib13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.yapd.2023.04.002_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.yapd.2023.04.002_bib15","article-title":"The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): objectives and preliminary results","volume":"120","author":"Millot","year":"2012","journal-title":"ASH Annu Meeting Abstracts"},{"issue":"22","key":"10.1016\/j.yapd.2023.04.002_bib16","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.2018882233","article-title":"How I treat chronic myeloid leukemia in children and adolescents","volume":"133","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.yapd.2023.04.002_bib17","series-title":"Clinical practice guidelines in oncology; chronic myeloid leukemia, Version 1.2023","author":"NCCN","year":"2022"},{"issue":"1","key":"10.1016\/j.yapd.2023.04.002_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1600-0609.1977.tb01474.x","article-title":"The peripheral blood in chronic granulocytic leukaemia","volume":"18","author":"Spiers","year":"1977","journal-title":"Scand J Haematol"},{"issue":"7","key":"10.1016\/j.yapd.2023.04.002_bib19","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.yapd.2023.04.002_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.03.020","article-title":"Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia","volume":"115","author":"Millot","year":"2019","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.yapd.2023.04.002_bib21","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","article-title":"Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents","volume":"102","author":"Millot","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.yapd.2023.04.002_bib22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/pbc.25803","article-title":"Leukostasis in children and adolescents with chronic myeloid leukemia: Japanese pediatric leukemia\/lymphoma study group","volume":"63","author":"Kurosawa","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"24","key":"10.1016\/j.yapd.2023.04.002_bib23","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.yapd.2023.04.002_bib24","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","article-title":"Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial","volume":"32","author":"Suttorp","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.yapd.2023.04.002_bib25","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","article-title":"Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study","volume":"104","author":"Champagne","year":"2004","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.yapd.2023.04.002_bib26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","article-title":"Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.yapd.2023.04.002_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40272-021-00446-2","article-title":"Tyrosine kinase inhibitors and beyond for chronic myeloid leukemia in children","volume":"23","author":"Phillips","year":"2021","journal-title":"Paediatr Drugs"},{"issue":"20","key":"10.1016\/j.yapd.2023.04.002_bib28","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.yapd.2023.04.002_bib29","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.yapd.2023.04.002_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbmt.2020.10.011","article-title":"The role of blood and marrow transplantation in treating pediatric chronic myelogenous leukemia in the era of tyrosine kinase inhibitors","volume":"27","author":"Veys","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.yapd.2023.04.002_bib31","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2016.03.012","article-title":"Allogeneic stem cell transplantation for patients with T315I BCR-ABL mutated chronic myeloid leukemia","volume":"22","author":"Xu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.yapd.2023.04.002_bib32","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.yapd.2023.04.002_bib33","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A\u00a0review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.yapd.2023.04.002_bib34","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/pbc.25551","article-title":"Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib","volume":"62","author":"Nickel","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.yapd.2023.04.002_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/pch\/11.2.103","article-title":"Adolescents and young adults with cancer: an orphaned population","volume":"11","author":"Fernandez","year":"2006","journal-title":"Paediatr Child Health"},{"issue":"17","key":"10.1016\/j.yapd.2023.04.002_bib36","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.yapd.2023.04.002_bib37","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.yapd.2023.04.002_bib38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/pbc.26156","article-title":"Transition and transfer of childhood cancer survivors to adult care: a national survey of pediatric oncologists","volume":"64","author":"Kenney","year":"2017","journal-title":"Pediatr Blood Cancer"}],"container-title":["Advances in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310123000099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310123000099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:19:35Z","timestamp":1758745175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065310123000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0065310123000099"],"URL":"https:\/\/doi.org\/10.1016\/j.yapd.2023.04.002","relation":{},"ISSN":["0065-3101"],"issn-type":[{"value":"0065-3101","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Myeloid Leukemia in Children and Adolescents","name":"articletitle","label":"Article Title"},{"value":"Advances in Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yapd.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}